Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

BACKGROUND: Incretin-based agents, including dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 agonists (GLP-1As), work via GLP-1 receptor for hyperglycemic control directly or indirectly, but have different effect on cardiovascular (CV) outcomes. The present study is to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zeqing, Chen, Xi, Lu, Puhan, Zhang, Jianhua, Xu, Yongping, He, Wentao, Li, Mengni, Zhang, Shujun, Jia, Jing, Shao, Shiying, Xie, Junhui, Yang, Yan, Yu, Xuefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333444/
https://www.ncbi.nlm.nih.gov/pubmed/28249585
http://dx.doi.org/10.1186/s12933-017-0512-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333444/
https://www.ncbi.nlm.nih.gov/pubmed/28249585
http://dx.doi.org/10.1186/s12933-017-0512-z

Ejemplares similares